| abstract |
Novel pharmaceutical compositions have been described for the treatment of retroviral infections through the use of enteral or parenteral administration containing one of the reverse transcriptase inhibitors, namely, Zidovudine, Lamivudine or Stavudine in clinically effective amounts and Meldonium, as well as pharmaceutically applicable excipients. . The inclusion of Meldonium in these pharmaceutical compositions has been shown to decrease the cardiotoxicity and neurotoxicity of the reverse transcriptase inhibitor. |